COMMUNIQUÉS West-GlobeNewswire

Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer
26/02/2026
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
26/02/2026
SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and [...]
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
26/02/2026
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule [...]
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
26/02/2026
MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, [...]
Iovance Biotherapeutics to Present at Upcoming Conferences
26/02/2026
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Cannara Announces Graduation to the Toronto Stock Exchange
26/02/2026
MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
26/02/2026
Revenue and Adjusted EBITDA results delivered in line with stated full-year targets Full‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2, [...]
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
26/02/2026
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the [...]
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
26/02/2026
Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 [...]
Aveanna Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call
26/02/2026
ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its fourth quarter and full year results before the market open on [...]
Enovis Announces Fourth Quarter and Full Year 2025 Results
26/02/2026
Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 [...]
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
26/02/2026
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA [...]
Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
All 2025 Operating and Financial Metrics At or Above High End of Guidance Ranges Full-year 2025 Net Income +59.3% from 2024 Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024 Full-year 2025 Net Cash [...]
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
26/02/2026
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter [...]
Trading by management and close relations of management
26/02/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
Invitation to the 2026 Annual General Meeting
26/02/2026
The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the [...]
Phonak ambassadors spotlight hearing health for the next generation on World Hearing Day
26/02/2026
STÄFA, Switzerland, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Phonak, a global leader in innovative hearing solutions, will mark World Hearing Day on March 3 with a global campaign across three continents, putting youth hearing [...]
Pulselight to host senior health leaders for panel on ‘efficiency drive’ to reduce NHS waste and duplication
26/02/2026
Former UK Health Minister Lord Bethell and former Deputy Chief Medical Officer Professor Sir Jonathan Van-Tam, join Pulselight for panel on unlocking NHS efficiency LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pulselight, [...]
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
26/02/2026
$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year ‑ over ‑ year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating [...]

Pages